Insider buying last 90 days
$200Kin 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 26 | Morano Susan E director | Purchase | $100K |
| Aug 7 | David C Habiger Director | Purchase | $100K |
From Form 4 filings, dated to when each was filed.
NYSE: BSX
Boston Scientific (BSX) Stock Analysis & Forecast
Nov 4 close
$45.82+2.32 (+5.3%)
Gekko Brief
Nov 4 closeBoston Scientific closed at $45.82 on 4 November 2026, +5.3% on the day. The price sits between the 50-day ($44.48) and 200-day ($55.84) moving averages, inside a 52-week range of $39.57 to $105.65. The GekkoIndex reads 54.3, in the Neutral zone, down 8.2 points over five sessions. Gekko Fair Value is $62.62, so the price is 26.8% below it.
The next earnings report is due on 3 February 2027, 90 days away (before open). Over the last 8 reports the company beat the earnings estimate 8 times, with an average move of 5.6% across the report. Smart-money activity over the last 90 days includes 2 open-market insider purchases and 2 Congress purchases and 0 sales. Seasonally, the next 20 trading days from this point averaged +2.6% over the last 5 years, rising in 3 of them.
21 firms rate the stock: 14 buy, 7 hold and 0 sell, with a consensus target of $49.60. A typical daily move is about 3.9%, and a typical 20-day move about 4.3%. On the swing-trade checklist, 4 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 4, 2026 close.
Boston Scientific price vs fair value
Close $45.82200-day averageGekko Fair Value $62.62
Boston Scientific quick facts
- Market cap
- $66.40B
- P/E ratio
- 18.7
- Forward P/E
- 12.9
- EPS, TTM
- $2.37
- Revenue, TTM
- $21.07B
- Profit margin
- 16.6%
- Dividend yield
- —
- Beta
- 0.59
- Volume
- 34.48M avg 19.75M
- 1-year return
- −53.5%
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±4.3%
- 50-day average
- $44.48
- 200-day average
- $55.84
- Next earnings
- Feb 3 before open
- Shares outstanding
- 1.45B
Boston Scientific swing-trade checklist
Boston Scientific scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
- Trendmixed
Averages disagree
Close $45.82 sits between the 50-day ($44.48) and 200-day ($55.84) averages, or the averages disagree.
See the chart - GekkoIndexmixed
54.3, Neutral
Reading 54.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
26.8% below
Price is 26.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 2 open-market insider purchases; Congress 2 buys / 0 sales.
See smart money - Earnings risksupportive
Reports in 90 days
Next report Feb 3, 2027, 90 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+2.6% on average
From this point in the calendar, the next 20 trading days averaged +2.6% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Boston Scientific stock chart and price history
Boston Scientific closed at $45.82 on Nov 4, 2026, −53.5% over the past year, inside a 52-week range of $39.57 to $105.65.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.6%
- 3 months
- −7.1%
- 6 months
- −18.2%
- 1 year
- −53.5%
The full BSX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BSX in Gekko
Follow Boston Scientific through every session
Put BSX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BSX in GekkoFree for 7 days. No credit card required.
About Boston Scientific
Boston Scientific designs, makes, and sells medical devices used across a range of interventional specialties. It is known for products that support the diagnosis and treatment of conditions affecting the heart, blood vessels, digestive and respiratory systems, urinary and pelvic health, the nervous system, and certain cancers, including catheters, stents, implantable cardiac devices, neurostimulation systems, and tools for cardiac mapping and imaging.
The company organizes its work into three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. MedSurg covers gastrointestinal, pulmonary, urological, and pelvic health tools. Rhythm and Neuro includes devices for cardiac rhythm management, cardiac mapping and ablation, and neurological treatments such as spinal cord stimulation and deep brain stimulation. Cardiovascular spans coronary stents, structural heart therapies, peripheral artery and vein treatments, and cancer-related products such as embolization devices and ablation systems.
Boston Scientific was founded in 1979 and is headquartered in Marlborough, Massachusetts. Its shares are listed on the NYSE under the ticker BSX.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- bostonscientific.com
Boston Scientific GekkoIndex: the smart money zone
Boston Scientific’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.3, in the Neutral zone, down 8.2 points over five sessions.
54.3Neutral
Down 8.2 points over five sessions, from the Accumulation zone.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | +0.2% | −3.4% | ||
| Accumulation | 224 | −0.5% | −2.3% | ||
| Neutral (current zone) | 349 | −0.1% | +0.1% | ||
| Distribution | 73 | +0.6% | +1.6% | ||
| Selling | 4 | Too few readings yet | |||
Average BSX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BSX price, zone by zone.Track BSX in Gekko
Is Boston Scientific stock overvalued? Gekko Fair Value
Boston Scientific trades 26.8% below Gekko Fair Value of $62.62, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Boston Scientific shares are worth, recalculated every trading day.
$62.62
Gekko Fair Value, Nov 4, 2026
26.8% Undervalued
At the end of Aug 2026 the price was 37.3% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open BSX in Gekko
Boston Scientific insider and Congress trading
Insiders filed 2 open-market purchases in Boston Scientific worth $200K, and members of Congress disclosed 2 purchases and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
2trades disclosed: 2 purchases and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Sep 11 traded Aug 18 |
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Sep 7 traded Aug 10 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Boston Scientific has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $2.00B
- As a share of market cap
- 3.01%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
3of the funds Gekko tracks hold BSX.
1added1opened1trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Boston Scientific earnings: next date and track record
Boston Scientific reports on Feb 3, 2027, before the open (90 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 3, 2027
Expected before the open, 90 days away
- EPS estimate
- $0.79
- Revenue estimate
- $5.20B
8 of 8reports beat the EPS estimate
±5.6%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 28, 2026 AI summary
- What they said
- BSX Q3 2026 organic sales grew 1.5%, missing the 3-5% guidance, while adjusted EPS of $0.73 declined 3% versus guidance of $0.80-$0.82. A cybersecurity incident reduced sales growth by ~300bps and EPS by $0.07. EP and Watchman franchise headwinds, combined with China pricing pressure, are weighing on results. Full-year 2026 organic revenue growth guided to 4% with EPS of $3.16-$3.18.
- Guidance
- Q4 2026 guided to organic revenue decline of -1% to -3% and EPS of $0.77-$0.79, including 200-300bps cyber incident impact. Management expects 2027 to be a trough year, warning sales and adjusted EPS growth will be challenged excluding the pending Penumbra acquisition.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 28, 2026 | $0.73 est $0.72 | $5.14B est $5.06B | −5.3% |
| Jul 29, 2026 | $0.86 est $0.83 | $5.44B est $5.38B | −0.1% |
| Apr 22, 2026 | $0.80 est $0.79 | $5.20B est $5.17B | +10.4% |
| Feb 4, 2026 | $0.80 est $0.78 | $5.29B est $5.28B | −15.3% |
| Oct 22, 2025 | $0.75 est $0.71 | $5.07B est $4.97B | +2.5% |
| Jul 23, 2025 | $0.75 est $0.73 | $5.06B est $4.89B | +3.0% |
| Apr 23, 2025 | $0.75 est $0.67 | $4.66B est $4.57B | +6.4% |
| Feb 5, 2025 | $0.70 est $0.66 | $4.56B est $4.42B | +1.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Boston Scientific stock forecast and analyst price targets
Analysts’ average 12-month price target for Boston Scientific is $49.60, +8.2% from the last close, from 21 firms rating the stock in the last 90 days.
$49.60consensus 12-month target, +8.2% from the last close
Now $45.82Avg $49.60
Low $44High $60
Each firm’s latest rating in the last 90 days: 21 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 30 | Bank of America Securities | $54 | +17.9% |
| Oct 30 | Barclays | $45 | −1.8% |
| Oct 30 | TD Cowen | $46 | +0.4% |
| Oct 29 | Leerink Partners | $50 | +9.1% |
| Oct 29 | Robert W. Baird | $51 | +11.3% |
+0.1%average 20-day move after past Neutral readings
+2.6%average move over the next 20 trading days in the last 5 years
±3.9%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Boston Scientific seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Boston Scientific averaged +2.6% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 3 of 5 |
| Next 10 trading days | +2.2% | 4 of 5 |
| Next 15 trading days | +2.0% | 4 of 5 |
| Next 20 trading days | +2.6% | 3 of 5 |
| Next 30 trading days | +2.9% | 3 of 5 |
For scale, BSX’s typical 20-trading-day move in either direction is about 4.3%.
Boston Scientific market cap and key statistics
Boston Scientific’s market cap is $66.40B, with a P/E ratio of 18.7 and revenue of $21.07B over the last twelve months.
Valuation
- Market cap
- $66.40B
- P/E ratio
- 18.7
- Forward P/E
- 12.9
- EPS, TTM
- $2.37
- Gekko Fair Value
- $62.62
Trading
- Volume
- 34.48M
- Avg volume, 20 days
- 19.75M
- 52-week high
- $105.65
- 52-week low
- $39.57
- Shares outstanding
- 1.45B
Financials
- Revenue, TTM
- $21.07B
- Profit margin
- 16.6%
- Return on equity
- 14.3%
- Quarterly earnings growth, YoY
- −21.5%
Risk and income
- Beta
- 0.59
- Typical daily move
- ±3.9%
- Typical 20-day move
- ±4.3%
Boston Scientific stock news this week
Coverage of Boston Scientific this week reads negative: 3 positive, 4 neutral and 9 negative headlines.
- Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 YearsBenzinga, Nov 4
- RevMedica Appoints Former Boston Scientific Executive Mike Jones as Chief Executive OfficerYahoo Finance UK, Nov 4
- BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays WeakTradingView, Nov 4
- Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?The Globe and Mail, Nov 4
- Form 4 Boston Scientific Corp: Miriam O’Sullivan (SVP, Chief HR Officer) For: 1 NovemberInvesting.com Nigeria, Nov 4
- Form 4 Boston Scientific Corp: Miriam O’Sullivan (SVP, Chief HR Officer) For: 1 November By Investing.comInvesting.com India, Nov 4
Boston Scientific peers
Boston Scientific’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 14.5% above |
| ABTAbbott Laboratories | Distribution | 8.0% below |
| ISRGIntuitive Surgical | Distribution | 30.4% above |
| DHRDanaher | Neutral | 3.6% above |
| MDTMedtronic | Neutral | 16.0% below |
| SYKStryker | Distribution | 6.5% above |
A peer links to its own page where one exists.
Boston Scientific stock FAQ
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $66.40B at the Nov 4, 2026 close of $45.82, with 1.45B shares outstanding. The shares trade on a P/E ratio of 18.7.
What is the Boston Scientific stock forecast?
The consensus analyst 12-month price target for Boston Scientific is $49.60, +8.2% from the last close. Of the 21 firms that rated the stock in the last 90 days, 14 rate it a buy, 7 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Boston Scientific stock overvalued or undervalued?
On Gekko’s estimate Boston Scientific is undervalued: the Nov 4, 2026 close of $45.82 is 26.8% below Gekko Fair Value of $62.62. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Boston Scientific report earnings next?
Boston Scientific is expected to report on Feb 3, 2027, before the market opens (90 days away). Analysts expect earnings of $0.79 per share on revenue of $5.20B. Boston Scientific beat the earnings estimate in 8 of its last 8 reports, moving 5.6% on average across the report.
What is Boston Scientific’s 52-week high and low?
Boston Scientific’s 52-week high is $105.65 and its 52-week low is $39.57; it closed at $45.82 on Nov 4, 2026, −53.5% over the past year. Over the last five years the shares peaked at $109.50 on Sep 9, 2025.
Is Boston Scientific stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (fair value, smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Boston Scientific the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.